Permira-backed Quotient Sciences takes an innovative approach to drug development. Here, Silvia Oteri, Partner at Permira, and Mark Egerton, CEO of Quotient Sciences, discuss how Quotient enables its pharmaceutical and biotech customers to reduce the time and cost of bringing a new drug to market.
22 Sep 2022
